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Abstract
Background: Fibrinogen and prothrombin have been suggested to become rate limiting in trauma associated
coagulopathy. Administration of fibrinogen is now recommended, however, the importance of prothrombin to
patient outcome is unknown.
Methods: We have utilized two trauma patient databases (database 1 n = 358 and database 2 n = 331) to investigate
the relationship of plasma prothrombin concentration on clinical outcome and coagulation status. Database 1 has
been used to assess the relationship of plasma prothrombin to administered packed red blood cells (PRBC), clinical
outcome and coagulation biomarkers (Prothrombin Time (PT), ROTEM EXTEM Coagulation Time (CT) and Maximum
Clot Firmness (MCF)). ROC analyses have been performed to investigate the ability of admission coagulation biomarkers
to predict low prothrombin concentration (database 1), massive transfusion and 24 h mortality (database 1 and 2). The
importance of prothrombin was further investigated in vitro by PT and ROTEM assays in the presence of a prothrombin
neutralizing monoclonal antibody and following step-wise dilution.
Results: Patients who survived the first 24 h had higher admission prothrombin levels compared to those who
died (94 vs.67 IU/dL). Patients with lower transfusion requirements within the first 24 h (≤10 units of PRBCs)
also had higher admission prothrombin levels compared to patients with massive transfusion demands (>10 units of
PRBCs) (95 vs.62 IU/dL). Admission PT, in comparison to admission ROTEM EXTEM CT and MCF, was found to be a
better predictor of prothrombin concentration <60 IU/dL (AUC 0.94 in database 1), of massive transfusion (AUC 0.92
and 0.81 in database 1 and 2 respectively) and 24 h mortality (AUC 0.90 and 0.78 in database 1 and 2, respectively). In
vitro experiments supported a critical role for prothrombin in coagulation and demonstrated that PT and ROTEM
EXTEM CT are sensitive methods to measure low prothrombin concentration.
Discussion: Our analyses suggest that prothrombin concentration at admission is predictive of mortality and
transfusion and indicates that prothrombin and fibrinogen are rate limiting in coagulopathy.
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Conclusions: Admission PT is predictive of low prothrombin concentration and clinical outcome. PT could
therefore be used as a surrogate for prothrombin concentration and further evaluation of point-of-care
devices for faster PT analysis is warranted.
Keywords: Prothrombin, Coagulopathy, Severe bleeding, PT, ROTEM, Biomarker
Background
Hemorrhage is still a common cause of death in
trauma. Even when patients are rapidly brought to
hospital and are treated according to current trauma
guidelines, patients may die because of bleeding that
cannot be controlled [1, 2]. Coagulopathy is associ-
ated with worse outcomes and may develop during
hemorrhage or transfusion therapy [3–5]. Fibrinogen
and prothrombin have been suggested to be the first
coagulation factors to become rate limiting for coagu-
lation in such situations [6]. While the administration
of fibrinogen is now recommended to restore fibrino-
gen levels [7–9], the importance of prothrombin in
trauma-induced coagulopathy and patient outcome is
unclear.
In experimental models of dilutional coagulopathy,
administration of recombinant human (rh) prothrombin
alone or in combination with fibrinogen improved survival,
reduced blood loss and improved coagulation when
measured by ROTEM and PT [10, 11]. Administra-
tion of prothrombin-containing concentrates may
therefore be useful also in trauma patients with coag-
ulopathy. Measurement of prothrombin concentration
is necessary to identify patients with low levels and
address the concern that over supplementation could
lead to increased thrombotic risk [12–14]. However,
since central lab analyses of plasma samples for pro-
thrombin concentration are too slow, there is a need
for surrogate biomarkers to identify patients with low
prothrombin concentration. We have therefore con-
ducted analyses of prothrombin levels in a prospective
observational cohort from a London Trauma Centre
and extended analyses on outcomes in an independ-
ent cohort from the Medical University of Innsbruck.
The aims of the study were, firstly, to investigate the
consequence of admission prothrombin concentration on
massive transfusion (more than 10 PRBC units) and mor-
tality at 24 h. Secondly, to determine the relationship be-
tween admission biomarkers (PT, ROTEM EXTEM CT
and MCF) and prothrombin concentration, and thirdly, to
understand the ability of admission biomarkers to act as a
surrogate for low prothrombin concentration and predict
outcome. To further evaluate the individual role of pro-
thrombin on PT and ROTEM biomarkers, in vitro studies
were performed to investigate the effect of specific pro-
thrombin depletion.
Methods
Analyses of prospective observational cohort studies
Databases
Database 1 (London) was generated from the Activation
of Coagulation & Inflammation in Trauma (ACIT) study,
a prospective observational cohort study conducted at the
Royal London Hospital, London, UK. Patient samples
used in this study were collected between January 2008
and September 2013. The ACIT study was reviewed and
approved by the UK Regional Ethics Committee [15]. All
adult trauma patients (>15 years) who met the local
criteria for full trauma team activation were eligible for
enrollment and recruited into the study when research
personnel were present (08:00-00:00 daily). Exclusion cri-
teria were: arrival in the emergency department 2 h after
injury; the administration of 2000 mL of intravenous fluid
before emergency department arrival; transfer from
another hospital; and burns covering 5% of the total body
surface area. Patients were retrospectively excluded if they
declined to give consent to use research samples collected,
were found to be taking anticoagulant medications, had
moderate or severe liver disease or a known bleeding
diathesis.
Database 2 (Innsbruck) was generated from the Diagno-
sis and Treatment of Trauma-Induced Coagulopathy
(DIA-TRE-TIC) study, a single center prospective cohort
study conducted at Innsbruck Medical University Hospital
between July 2005 and July 2008. Adult poly-trauma
patients, who were admitted to the Level I Trauma Center
at Innsbruck Medical University Hospital were eligible for
enrollment and recruitment into the study. Starting in
January 2006, patients with isolated traumatic brain injury
were enrolled as well. Severe poly-trauma was defined as
an Injury Severity Score (ISS) of ≥15 resulting from injury
of at least two body regions. Isolated head injury was
defined as a Glasgow Coma Score of ≤14 after blunt head
trauma in patients with an Abbreviated Injury Score (AIS)
of <3 in any other body region. Exclusion criteria were:
patients <18 years, penetrating injuries, admittance to the
study hospital later than 12 h after trauma, pre-existing
coagulopathy, burn injury, malignant disease, avalanche
victims, or exhibition of non-head single trauma. The
study protocol was approved by the Ethics Committee of
Innsbruck Medical University. The need for written in-
formed consent was waived because study-related blood
sampling was judged a minimal-risk intervention and all
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patients were treated according to routine institutional
treatment guidelines [16].
Data have been collected by each trauma center and
locally available methods have been used for sample ana-
lyses. Prothrombin concentration for database 1 was
measured in the hospitals central lab with a prothrom-
bin clot assay and a pooled normal plasma standard
calibrated to an international standard for prothrombin.
In both hospitals ROTEM analyses were performed
locally to the emergency department, whilst PT was ana-
lysed in the hospitals central lab. In order to evaluate
the predictive ability of admission coagulation biomarker
data under real conditions no attempt was made to
monitor variation or standardize sample analyses be-
tween hospitals.
Outcome measures
The main outcomes considered were prothrombin con-
centration (IU/dL) measured at admission, total amount
of PRBC (units) delivered during the first 24 h, and the
proportion survival (%) at 24 h after admission. Three
binary variants of these outcomes were also defined: low
prothrombin (indicator of concentration <60 IU/dL at
admission), massive transfusion (indicator of >10 PRBC
units) and mortality at 24 h (indicator of death within
the first 24 h). Biomarkers included in analyses were
fibrinogen concentration, EXTEM CT, EXTEM MCF
and PT, all measured at admission.
Statistical analyses
The relationship between prothrombin concentration at
admission with survival at 24 h and, the amount PRBC
delivered during the first 24 h after admission, as well as
with fibrinogen concentration, EXTEM CT, EXTEM
MCF and PT, was investigated graphically for database
1. Furthermore, Spearman’s correlation coefficient was
used to quantify the relationships between prothrombin
concentration and fibrinogen concentration, EXTEM
CT, EXTEM MCF and PT values. Prothrombin and
fibrinogen concentration, EXTEM CT, EXTEM MCF
and PT are all admission values.
For each of the three binary outcomes the predictive
ability of EXTEM CT, of EXTEM MCF and of PT
was assessed using receiver operating characteristic
(ROC) analyses. Comparison between EXTEM CT,
EXTEM MCF and PT was quantified by the area
under the ROC (AUC). DeLong’s test [17] was used
to assess statistical difference between the AUCs.
ROC analyses were performed using R package pROC
[18]. Graphs and analyses were performed using R
version 3.1.0 and above (R Foundation for Statistical
Computing, Vienna, Austria). The significance level
used was 0.05.
In vitro prothrombin studies
Materials
The prothrombin neutralizing anti-human monoclonal
antibody AB730006 ba SP14-046 IgG2b was obtained
from MedImmune (Cambridge, UK).
Blood samples intended for in vitro studies at AstraZe
neca R&D, Gothenburg, Sweden were drawn from 5
healthy volunteers (3 males and 2 females) after in-
formed consent and approval from the local Gothenburg
ethical committee (ethical permit number: 033-10). The
sample size was not determined from a formal power
calculation for this particular study but was based on
previous experience of the assay methods used. Whole
blood was collected into polypropylene tubes from
Sarstedt (Nümbrecht, Germany) by free flow from a 17-
gauge Venflon needle from Becton Dickinson Infusion
Therapy AB (Helsingborg, Sweden). The first 2 mL of
the collected blood was discarded. Then nine volumes
blood was mixed with one volume 0.11 M trisodium
citrate. Of the 50 mL whole blood collected per donor
10 mL was used for preparation of platelet poor plasma
by centrifugation of the citrated blood at 2000 x g in a
swing-out rotor for 20 min at 20 °C prior to transfer of
the plasma supernatant to a new sample tube.
Rotational thromboelastometry
Clot elasticity was measured by a standard coagulation
test (EXTEM+ STARTEM reagents, Tem Innovations
GmbH, Munich, Germany) using ROTEM equipment
(Tem Innovations GmbH). Citrated blood, as described
above, was pre-incubated with prothrombin neutralizing
anti-human antibody (MedImmune) 0.021, 0.041, 0.062
and 0.083 mg/mL to study the effect of a specific
decrease in prothrombin. A serial dilution was also
performed to study the effect of a simultaneous decrease
in all coagulation and anticoagulation factors. This step-
wise dilution was done with 13 mM sodium citrate
buffer starting at 100% whole blood and then 70, 50, 40,
30, 20, 10 and 5% whole blood. Samples were kept at
37 °C for 10 min before starting ROTEM analysis.
Sodium citrate was included in the dilution buffer to
keep the citrate concentration constant during dilution
of the citrated whole blood. Thus, the free calcium con-
centration following addition of calcium for recalcifying
purposes as part of the standard assay was kept constant.
EXTEM CT and EXTEM MCF were evaluated by adding
300 μL of the incubated blood samples into the ROTEM
equipment together with 20 μl EXTEM reagent and
20 μL STARTEM reagent according to the manufacturer
instructions. All samples were run for 60 min.
Prothrombin time
Citrated plasma was pre-incubated with prothrombin
neutralizing anti-human antibody (MedImmune) 0.021,
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0.041, 0.062, 0.083, 0.124 and 0.165 mg/mL or diluted
with 20 mM sodium citrate starting at 100% and then 70,
50, 40, 30, 20, 10 down to 5% plasma and kept at 37 °C for
9 min before PT was measured by adding 25 μL plasma to
the KC 10 A micro coagulometer (Amelung, Lemgo,
Germany). Dilution with a sodium citrate buffer for
ROTEM analysis was performed as described for the
diluted whole blood samples although the concentration
of citrate had to be increased to compensate for the lack
of hematocrit in plasma. After a 1 min incubation period
at 37 °C in the coagulometer, 50 μL of Thromborel® S
(Siemens Healthcare GmbH, Marburg, Germany) was
added and the time to coagulation was measured.
Maximum measurement time was 15 min.
Plasma concentration of prothrombin
Prothrombin functional activity was measured in the
antibody-treated and diluted blood/plasma samples
using a chromogenic prothrombinase end-point method
(PI 200040 Rox Prothrombin, Rossix AB, Mölndal,
Sweden) and a SPECTRAmax plate reader (Molecular
Devices, California, USA). As a standard a recombinant
prothrombin preparation calibrated to the NIBSC 98/
590 standard was used. One mg prothrombin was found
to be equivalent to 8.74 IU. This information was used
to calculate IU/dL from the mg/mL result obtained with
the prothrombinase assay.
Results
Association of prothrombin concentration with mortality
and transfusion demand in patients
Data including survival, administered PRBC and admis-
sion PT, EXTEM CT and MCF were available from 358
patients from London (database 1) and 331 patients from
Innsbruck (database 2) (Table 1). Prothrombin was not a
routine biomarker for analysis at the Medical University
of Innsbruck and therefore the number of patients with
admission data was limited. Database 2 was therefore only
used where analyses was independent of prothrombin.
The characteristics of the two populations differed in
injury severity score (ISS: median 13 and 34 in database
1 and 2 respectively), percentage of patients receiving
one or more PRBC units (29 and 44%), and also in age,
temperature, systolic blood pressure and platelets
(Table 1).
Survival at 24 h was associated with higher prothrom-
bin plasma concentrations at admission with a change in
the proportion of survivors occurring within the range
of 50–70 IU/dl (Fig. 1a). A total of 55, 26, and 9 patients
had admission prothrombin plasma concentration below
70, 60 and 50 IU/dl respectively, and the corresponding
surviving percentages at 24 h were 89, 81 and 78%. In
database 1, patients who survived the first 24 h had a
median prothrombin concentration of 94 IU/dL
compared to 67 IU/dL for those who did not survive.
Patients with an increased transfusion demand (units of
PRBC given within the first 24 h) also had a lower pro-
thrombin concentration at admission (Fig. 1b). Patients
receiving ≤10 units PRBC during the first 24 h had a
median prothrombin concentration of 95 IU/dL com-
pared to 62 IU/dL for those who received >10 units.
Impact of prothrombin concentration on EXTEM CT,
EXTEM MCF and PT in vitro
To further investigate the importance of prothrombin
concentration on coagulation we performed in vitro ex-
periments in blood or citrated plasma from five healthy
volunteers in which the prothrombin concentration was
either gradually reduced by step-wise dilution or by the
addition of increasing amounts of a monoclonal antibody
neutralizing the prothrombin activity. Specific inhibition
or dilution reduced the prothrombin concentration and
had a dramatic effect on coagulation when measured by
PT or EXTEM CT. With the PT assay, the transition point
Table 1 Patient characteristics at admission to emergency
department, or within 24 h of admission (24 h survival, and ≥1







Men, n (%) 288 (80%) 259 (78%)
Age, years 35 (23–50) 43 (27–56)
Time from injury, minutes 76 (58–101) 75 (55–120)
Glasgow Coma Score (GCS) 15 (14, 15) 11 (6–15)
Injury Severity Score 13 (5–27) 34 (24–45)
Systolic BP, mmHg 132 (110–150) 120 (100–140)
Temp, °C 35.8 (35.1–36.5) 35.0 (34.2–36.0)
Hct 0.4 (0.37–0.43) 0.34 (0.28–0.38)
Platelets, 109/L 233 (194–273) 170 (139–203)
Hb, g/dL 13.8 (12.5–14.9) 11.6 (9.5–13.1)
AT, IU/dL 94 (82–104) 68 (56–81)
Factor VII, IU/dL 94 (76–118) 83 (50–98)
Factor X, IU/dL 96 (82–112) 69 (46–88)
24 h survival, n (%) 347, (97%) 308, (92%)
≥1 PRBC units, n (%) 104 (29%) 148 (44%)
Prothrombin, IU/dL 93 (77–105) 68 (55–86)
Fibrinogen, g/L 2.2 (1.7–2.7) 2.1 (1.6–2.6)
EXTEM CT, seconds 62 (50–77) 63 (55–74)
EXTEM MCF, mm 60 (56–63) 52 (46–57)
PT, seconds 11.1 (10.6–11.8) 14.9 (13.1–17.0)
aAt most 6% missing values in any variable except for Time from injury, Temp,
and GCS which had 10, 36 and 44% missing values respectively
bFactor VII, Factor X and Prothrombin were missing in 86% of the subjects,
Time from injury and Temp in 20 and 62%, respectively. The rest of the
variables had missing values in at most 4% of the 331 subjects
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for a prolonged coagulation time occurred at similar
concentrations, approximately 50–58 IU/dL prothrombin
(Fig. 2a). The EXTEM CT was first prolonged at approxi-
mately 67 IU/dL prothrombin with the neutralizing anti-
body added, but only at approximately 44 IU/dL when the
blood was diluted (Fig. 2b). EXTEM MCF showed no
decrease when only prothrombin was increasingly neutral-
ized until very low concentrations remained at which
point it dropped dramatically (Fig. 2c). This was in
contrast to the almost linear decline when the blood sam-
ple was step-wise diluted.
Association of admission prothrombin concentration with
PT or EXTEM CT and EXTEM MCF in patients
To investigate if currently available biomarker assays could
be used to identify patients with low prothrombin plasma
concentration we examined how admission prothrombin
concentration correlated with admission fibrinogen concen-
tration, EXTEM CT, EXTEM MCF and PT in database 1.
There was a significant correlation between prothrombin
concentration with fibrinogen concentration and all coagu-
lation endpoints tested (Fig. 3a–d). Spearman’s correlations
for PT and prothrombin were −0.56, p-value < 0.001, for
CT and prothrombin −0.11, p-value = 0.04, for fibrinogen
and prothrombin 0.55, p-value < 0.001 and finally for MCF
and prothrombin 0.35, p-value < 0.001.
Assessment of PT, EXTEM MCF and EXTEM CT as
predictors of prothrombin concentration and outcome in
patients
The ability of PT, EXTEM MCF and EXTEM CT bio-
markers to predict the presence of low prothrombin
concentration (<60 IU/dL at admission), massive trans-
fusion (>10 PRBC units within the first 24 h) and mor-
tality within the first 24 h were compared using ROC
analyses. The AUC of a ROC provides an assessment of
the overall value of the biomarker as a predictor. Based
on database 1, the AUCs of PT, of EXTEM CT and of
a
b
Fig. 1 24 h survival a and amount of PRBC delivered during the first 24 h after admission b are plotted versus prothrombin concentration at
admission for database 1. For clarity prothrombin concentration is divided into intervals (ninterval = (3, 6, 17, 29, 44, 61, 67, 66, 32, 33)). In the upper
graph a proportion of 24 h survival is plotted versus prothrombin concentration interval, and in the lower graph b distribution of units of PRBC
delivered during the first 24 h is plotted versus prothrombin concentration interval using box plots (box representing 25th, median (dot) and 75th
percentiles, whiskers go out to 10th and 90th percentiles). Note: only 11 out of the 358 patients included in the graph died within 24 h
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EXTEM MCF were 0.94, 0.68, and 0.78 respectively, for
prediction of low prothrombin concentration (Fig. 4a left
panel, Table 2). The AUC of PT differed significantly
from the AUC of EXTEM MCF, and from the AUC of
EXTEM CT (p <0.001 for both comparisons).
In order to complete the linkage between PT as a sur-
rogate biomarker for prothrombin concentration, ROC
analyses were performed to investigate the ability for PT
to predict survival and transfusion demand. Based on
database 1, PT was a significantly better predictor of
24 h mortality (AUC 0.90) and of massive transfusion
(AUC 0.92) than EXTEM CT or EXTEM MCF (Fig. 4a
and Table 2). In database 2, PT was the better predictor
and highest AUC for both endpoints, however, the
difference between PT and the two other biomarkers
was smaller for database 2 (Fig. 4b and Table 2).
.
Discussion
In this study we investigated the critical role of prothrom-
bin concentration in coagulopathy and prediction of out-
come in coagulopathic trauma patients. In addition, we
evaluated currently available coagulation biomarkers as
surrogates for detecting critically low plasma prothrombin
levels. Data presented indicates that admission prothrom-
bin plasma concentration can be used to predict increased
survival and a lower transfusion demand within the first
24 h following admission of the trauma patient and that a




Fig. 2 Impact of prothrombin depletion by adding increasing amount
of neutralizing antibody or step-wise dilution for a Prothrombin time
(PT), b ROTEM EXTEM Coagulation time (CT) and c ROTEM EXTEM
Maximum Clot Firmness (MCF). The PT experiment was performed
in citrated plasma from 5 different donors and the ROTEM EXTEM
experiments were performed in citrated whole blood from the
same 5 donors. The boxes represent 25th to 75th percentiles, the




Fig. 3 Prothrombin Time (PT) a EXTEM Coagulation Time (CT) b
Fibrinogen c and EXTEM Maximum Clot Firmness (MCF) d versus
prothrombin concentration for database 1. Loess curves (local
regression curves) are added to aid in evaluating the relationship
between variables. Fibrinogen concentration, CT and PT were log
transformed due to skewed distributions
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associated with a worse outcome (Fig. 1). During such a
coagulopathy many coagulation factors are simultaneously
reduced. This has been previously shown where coagula-
tion factors and biomarkers were analysed in coagulo-
pathic patients with INRs of 1.5–3 prior and post FFP
administration [19]. Similar to our findings, these patients
had a median prothrombin concentration of 34% of
normal before FFP administration and also reduced
concentrations of several other coagulation factors such as
Factor X and fibrinogen.
Since several coagulation factors are reduced in coa-
gulopathic trauma patients we investigated the specific
role of prothrombin concentration in coagulation by
in vitro experiments. Our in vitro data comparing spe-
cific neutralization of prothrombin by a prothrombin
neutralizing antibody and general dilution of all co-
agulation factors by serial dilution of blood or plasma,
showed that reduction in prothrombin concentration
had a dramatic effect on both PT and ROTEM CT.
Comparable data was found for specific neutralization
of prothrombin or general dilution of all coagulation
factors suggesting that prothrombin concentration is a
rate limiting factor in coagulation (Fig. 2). Our in vitro
results also support the usefulness of PT and EXTEM
CT as surrogate markers for direct measurement of
prothrombin concentration. EXTEM MCF is not appro-
priate due to the discrepancy between ROTEM MCF
obtained during step-wise dilution and neutralization of
prothrombin. This is thought to be due to that following
neutralization a proportion of prothrombin is still acti-
vated and is available to activate platelets and fibrinogen
which are at normal concentration. Since fibrinogen and
platelets are mainly responsible for building MCF the
same clot stability is reached eventually. In the case of
step-wise dilution, all coagulation factor concentrations
and platelet count are decreased and hence the almost
linear decrease in EXTEM MCF.
Extending in vitro findings to the trauma databases,
prothrombin concentration in trauma patients was also
reflected in the biomarkers PT, EXTEM CT and EXTEM
MCF. Furthermore, low prothrombin concentration was
correlated with a low fibrinogen concentration (Fig. 3).
This suggests that the trauma patients having low
fibrinogen and prothrombin concentrations are coagulo-
pathic due to coagulation factor consumption and/or
dilution. Since point-of-care (PoC) tests are not available
for the fast analysis of fibrinogen or prothrombin, surro-
gate coagulation markers could be used to identify
patients with low prothrombin concentrations. The idea
of early identification of patients in need of hemostatic
Fig. 4 ROCs for each of PT, EXTEM Maximum Clot Firmness (MCF) and EXTEM Coagulation Time (CT), when entered as single predictor of each
outcome indicator in the underlying logistic regression. a ROCs based on database 1. b ROCs based on database 2
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therapy by the use of coagulation assays is not new.
ROTEM and TEG, where available, are used for this
purpose and for guiding therapy [7–9, 20]. In hemorrhagic
patients the PT assay has as far as we are aware been used
to analyse retrospective data, although it is sometimes
used as a tool to confirm the effectiveness of hemostatic
therapy [21].
In the clinic, a cut-off value to define “low prothrombin”
is required in order to decide who will receive prothrom-
bin containing treatment and who will not. A cut-off value
for prothrombin is also needed for ROC analysis in order
to compare the sensitivity and specificity of biomarkers to
predict low prothrombin concentration. From Fig. 1, we
observed that there appears to be a change in the propor-
tion of survivors and the total amount of administered
PBRC within the prothrombin concentration range of 50–
70 IU/dL. Furthermore, in vitro data presented in Fig. 2
shows that decreasing prothrombin below a similar limit
has a large impact on PT and EXTEM CT. These two ob-
servations together provides evidence for a threshold in
prothrombin concentration within the range of 50–70 IU/
dL that is critical for coagulation. In order to evaluate bio-
marker predictivity we chose to evaluate 60 IU/dL as a
binary threshold for ROC analyses since a prothrombin
concentration below 60 IU/dL is considered to be out of
the normal range and therefore is reflective of a clinically
relevant cut-off.
ROC analyses suggests that PT is a better predictor of
low prothrombin concentration versus EXTEM CT and
EXTEM MCF. To check how sensitive the biomarker com-
parisons were to the choice of cut off level, we also per-
formed the analyses using < 70 IU/dL. The ranking of the
coagulation biomarkers remained the same independently
of whether the cut off was set to < 60 (Fig. 4) or < 70 IU/dL
(data not shown). Furthermore, PT was also the better
predictor of massive transfusion and mortality compared to
EXTEM CT and EXTEM MCF. We chose not to include
the amplitudes at 5 or 10 min (A5, A10) in our analyses
since they have been shown to correlate well to MCF
[22–24]. In the databases analysed even a small
increase in PT is associated with an increased risk. This
was observed in both independent databases despite
multiple differences in the severity of injury and inclu-
sion/exclusion criteria.
We believe that successful normalization of prothrom-
bin levels requires administration of a concentrate such
as the recombinant human prothrombin (MEDI8111)
that was recently evaluated in healthy volunteers [25]. In
support of this, administration of recombinant human
prothrombin alone was sufficient to reduce bleeding and
improve coagulation and survival time in coagulopathic
pigs [11]. In humans, however, the importance of having
a sufficiently high fibrinogen concentration has been
recognized [7] and from our database analyses we con-
firm that there is a strong correlation between admission
concentrations of fibrinogen and prothrombin (Fig. 3).
We cannot therefore distinguish between the specific
contribution of fibrinogen or prothrombin loss alone on
prolonged PT and coagulopathy but instead conclude
that prothrombin is depleted along with fibrinogen during
the development of coagulopathy and that replacement of
both factors is required to achieve hemostasis.
PT is a useful biomarker to identify eligible patients for
prothrombin replacement therapies although centrally
measured PT was used in the current databases which is
recognised to have limitations in guiding treatment due to
the slow turnaround time [26]. A number of PoC analysers
of PT are available e.g. CoaguChek XS system, Roche; i-
STAT system, Abbott, and need to be evaluated further for
this purpose. If this can be achieved, it seems possible that
in the future massive bleedings can be controlled or even
avoided by identification of coagulopathic patients depleted
in prothrombin by simple available PoC methodology.
Limitations
This study is based on analyses of two prospective obser-
vational cohorts. Since prothrombin concentration was
not routinely measured at the Medical University of
Innsbruck the number of patients with admission data
was limited. All analyses involving prothrombin were
Table 2 Summary of ROC analyses
Database Biomarker Low prothrombin Mortality 24 h Massive transfusion
AUC (95% CI) p-value AUC (95% CI) p-value AUC (95% CI) p-value
1
n = 358
PT 0.94 (0.88,0.96) – 0.90 (0.82,0.97) – 0.92 (0.89,0.98) –
EXTEM CT 0.68 (0.61,0.85) <0.001 0.66 (0.48, 0.82) <0.001 0.73 (0.55,0.80) <0.001
EXTEM MCF 0.78 (0.71,0.92) 0.003 0.81 (0.66,0.96) 0.04 0.81 (0.67,0.89) 0.04
2
n = 331
PT Not applicable 0.78 (0.68,0.89) – 0.81 (0.73,0.89) –
EXTEM CT 0.74 (0.62,0.86) 0.44 0.70 (0.61,0.78) 0.008
EXTEM MCF 0.67 (0.54,0.81) 0.03 0.75 (0.66,0.84) 0.05
The area under the ROC (AUC), was calculated in separate logistic regression models for each of the binary response variables low prothrombin (<60 IU/dL), mortality
24 h and massive transfusion (PRBC 24 h >10 units) for each of the three biomarkers PT, EXTEM CT and EXTEM MCF. The AUC p-value refers to a two-sided test of the
null hypothesis of no difference in AUC between PT and each of the two other biomarkers. In database 2 there were too few patients with admission prothrombin
concentrations to perform a valid ROC analysis
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therefore restricted to database 1 but database 2 was
included and added value by extending observations
regarding the predictivity of PT for mortality and trans-
fusion in two independent databases. There are also
multiple differences in the databases with regards to
severity of injury, inclusion/exclusion criteria, biomarker
analyses and importantly admission sampling time from
injury. While this variability does add noise to the study
we consider that it also adds strength in our conclusions
i.e. that despite these differences, PT is still predictive of
outcome and the better biomarker in both databases and
as a consequence supportive of broader clinical utility.
Conclusions
From this study we conclude that low prothrombin con-
centration with a cut-off in the range of 50–70 IU/dL
(corresponding to approximately 50–70% of normal pro-
thrombin concentration) together with low fibrinogen is
rate limiting for coagulation in bleeding trauma patients
and is associated with an increased risk for massive
transfusion and mortality. PT at admission is a sensitive
and specific predictor of low prothrombin concentration
and is a better predictor of massive transfusion and mor-
tality than the ROTEM parameters EXTEM CT and
EXTEM MCF used for current guidance.
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